HFA Premium Access

Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial

Presentation

About the speaker

Doctor Abhinav Sharma

McGill University Health Centre, Montreal (Canada)
1 presentation
0 follower

738 more presentations in this session

Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?

Speaker: Assistant Professor N. Radovanovic (Belgrade, RS)

Thumbnail

Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF

Speaker: Assistant Professor V. Kirillova (Ekaterinburg, RU)

Thumbnail

Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum

Speaker: Doctor D. Moysidis (Thessaloniki, GR)

Thumbnail

Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation

Speaker: Doctor A. Safiullina (Moscow, RU)

Thumbnail

Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?

Speaker: Doctor H. Santos (Barreiro, PT)

Thumbnail

Access the full session

ePoster session

Speakers: Doctor A. Sharma, Assistant Professor N. Radovanovic, Assistant Professor V. Kirillova, Doctor D. Moysidis, Doctor A. Safiullina...
Thumbnail

About the event

Image

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Related content

ESC Premium Access

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

27 August 2021

ESC Premium Access

Effect of empagliflozin in hfref patients treated with angiotensin receptor neprilysin inhibitor an analysis of EMPIRE HF

27 August 2021

ESC Premium Access

Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

27 August 2021

This platform is supported by

logo Novo Nordisk